泛亚微透: 泛亚微透第四届监事会第七次会议决议公告

Core Points - The company held its seventh meeting of the fourth supervisory board on June 13, 2025, where all resolutions were deemed legal and valid [1][2][3] Group 1: Capital Increase and Related Transactions - The supervisory board approved a proposal for capital increase and related transactions with a subsidiary, which complies with relevant laws and regulations, ensuring no significant impact on the company's financial status [1][2] - The company will increase its investment in Changzhou Lingtian Da New Energy Technology Co., Ltd. through cash and physical assets, pending shareholder approval [1][2] Group 2: New Related Transactions - The supervisory board approved a new related transaction involving a technology development contract with Jiangsu Yuanqing New Energy Technology Co., Ltd., affirming that the transaction is fair and does not harm the interests of non-related shareholders [2][3] Group 3: Loan Application - The company plans to apply for a fixed asset loan of up to RMB 120 million from China Everbright Bank for the intelligent manufacturing upgrade and expansion project of its dew point controller products [3] Group 4: Establishment of a Wholly-Owned Subsidiary - The supervisory board approved the establishment of a wholly-owned subsidiary in Wujin District, Changzhou, to enhance the company's strategic planning and competitiveness in the medical application field [3] Group 5: Capital Change and Articles of Association Revision - The company will change its registered capital from RMB 70 million to RMB 91 million following the completion of the 2024 equity distribution plan, necessitating revisions to its Articles of Association [4]